TB-500

What TB-500 is

Thymosin Beta-4 (Tβ4) is a small, naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene on the X chromosome and present in nearly all nucleated cells ^[1]. It was initially isolated from thymosin fraction 5 (TF5) in the thymus in 1981, and thymosin fraction 5 was originally authorized by the FDA to treat the primary immunodeficiency disease DiGeorge syndrome in clinical trials ^[1]. Tβ4 was subsequently identified as the body's most abundant G-actin-sequestering molecule — meaning its primary intracellular job is to bind and buffer free actin monomers, giving it direct influence over how cells change shape and move ^[2]. It is described as the most abundant member of the β-thymosin family and is regarded as the main G-actin sequestering peptide in mammalian tissue ^[3].

TB-500 refers specifically to a synthetic peptide corresponding to the central actin-binding domain of the Tβ4 sequence (residues 17–23, the heptapeptide Ac-LKKTETQ), which retains core pro-angiogenic and cell-migratory activity but lacks the full regulatory complexity of the intact parent peptide ^[4]. TB-500 has been promoted for tissue healing and musculoskeletal injury recovery, and has been investigated in preclinical models for its regenerative and cytoprotective effects, though it has far less direct human clinical evidence than the full-length Tβ4 molecule ^[5]. A 2026 scoping review mapped the published literature and noted that direct TB-500 evidence was limited to a single included study, with the broader literature on tissue healing derived predominantly from research on full-length Tβ4 ^[5].

What it is being researched for

1. Dermal wound healing and skin repair

One of the earliest and most replicated research areas for Tβ4 is cutaneous wound healing. Foundational animal studies demonstrated that Tβ4 application increased re-epithelialization, promoted collagen deposition, stimulated keratinocyte migration, and accelerated wound contraction in full-thickness wound models ^[6]. Tβ4 appears to act through multiple pathways simultaneously — promoting cell migration, building new blood vessels, dampening inflammation, blocking programmed cell death, and reducing scarring — a multi-target profile that has sustained scientific interest across decades of study ^[7]. A 2026 scoping review confirmed that wound and skin repair represent one of the most evidence-rich areas in the Tβ4 literature, though most studies remain preclinical ^[5].

2. Cardiac protection and myocardial repair

Tβ4 has been extensively researched for its ability to protect heart tissue following ischemic injury. Preclinical studies show it reduces infarct volume, preserves cardiac function, decreases cardiomyocyte apoptosis, and promotes blood vessel growth in large and small animal models of myocardial infarction ^[8]. The proposed mechanism involves Tβ4 forming a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt ^[2]. More recently, a randomized, placebo-controlled, double-blind trial in patients with acute ST-segment elevation myocardial infarction (STEMI) found that recombinant human Tβ4 significantly reduced infarcted areas and modulated the ErbB signaling pathway, though the authors noted further rigorous studies are needed ^[9]. A separate clinical observation found that elevated circulating Tβ4 levels were directly associated with improved cardiac symptoms six months after stem cell therapy in heart failure patients ^[10].

3. Corneal and ocular wound healing

Ocular research represents one of the most clinically advanced areas for Tβ4. Studies show Tβ4 significantly promotes corneal wound healing after injury by stimulating epithelial cell migration, modulating inflammatory mediators, and suppressing apoptosis ^[6]. A formulation known as RGN-259 (0.1% Tβ4 ophthalmic solution) progressed to Phase III clinical trials for neurotrophic keratopathy; while the primary endpoint was not met with statistical significance, a strong efficacy trend was observed and a significant difference in complete healing was seen two weeks after treatment cessation ^[11]. A Phase II trial for dry eye disease also reached the clinical stage, and as of the time of several publications, Tβ4-based ophthalmic therapy was still in active clinical development under FDA oversight ^[12]. Additional 2026 research explored whether adjunctive Tβ4 supports corneal nerve regeneration and restores visual function after infection, extending the research question beyond surface repair ^[13].

4. Angiogenesis and vascular biology

Tβ4's ability to promote new blood vessel formation is central to most of its other research areas. Laboratory studies established that a seven-amino-acid actin-binding motif within Tβ4 is essential for its angiogenic activity, and that this motif — closely corresponding to the TB-500 fragment — promotes endothelial cell migration and adhesion, tubule formation, and blood vessel sprouting ^[3]. Tβ4 was also found to upregulate vascular endothelial growth factor (VEGF) expression in endothelial cells and infarcted hearts, and to increase the proliferation, migration, and adhesion of endothelial progenitor cells ^[14]. Research in ischemic hindlimb models using human adipose-derived stem cells further demonstrated that Tβ4 enhances the angiogenic and regenerative capacity of transplanted cells ^[14].

5. Neurological protection and repair

A growing body of preclinical research investigates Tβ4's potential in the central nervous system. In mouse and rat models of acute cerebral infarction, Tβ4 significantly reduced infarct volume, improved neurological function scores, decreased cerebral edema, and suppressed neuronal pyroptosis via inhibition of the TLR4/NF-κB signaling pathway ^[15]. In models of multiple sclerosis (experimental autoimmune encephalomyelitis), Tβ4 was found to reduce inflammatory infiltrates and stimulate oligodendrogenesis — the production of myelin-producing cells — suggesting a potential remyelinating role ^[16]. A review of its role in neurodegenerative disorders proposed that Tβ4 modulates neuroinflammatory processes through its ability to suppress TLR signaling and upregulate the anti-inflammatory microRNA miR-146a ^[16]. All neuroprotective findings to date are from preclinical models; no human neurological trials have been published.

6. Hair follicle growth and activation

Interest in Tβ4 and hair biology arose serendipitously: while studying wound healing, researchers accidentally observed accelerated hair growth around wound edges, which led to dedicated investigation ^[7]. Subsequent animal studies confirmed that Tβ4 activates hair follicle stem cells, upregulates stem cell and angiogenesis-related gene pathways in follicular tissue, and induces rapid hair growth on dorsal skin of healthy mice ^[7]. A 2015 PLoS ONE study generated Tβ4-overexpressing mice and Tβ4 global knockout mice to mechanistically study this effect, observing faster regrowth and changes in follicle structure in animals with elevated Tβ4 levels ^[17]. Importantly, these findings are limited to animal models of forced hair removal, do not replicate conditions such as androgenetic alopecia, and no major regulatory authority has approved any Tβ4-based compound for hair loss ^[17].

7. Musculoskeletal and tendon repair

Despite being a primary driver of public and athletic interest in TB-500, musculoskeletal repair is among the least evidence-supported research areas in the published literature. A 2026 scoping review found that studies on cartilage and spine/intervertebral disc were comparatively sparse, and overall evidence directly relevant to musculoskeletal applications was unevenly distributed and largely preclinical ^[5]. Animal studies do show that Tβ4 promotes tissue repair in tendon-like structures, primarily through enhanced cell migration and angiogenesis, but specific tendon healing clinical trials in humans have not been conducted ^[18]. The scoping review further noted that human evidence was concentrated in ocular and wound/skin settings, not in muscle or joint tissue ^[5].

How it is thought to work

Tβ4's primary intracellular role is to sequester G-actin monomers — the individual building blocks of the cytoskeleton's actin filaments. By binding to free G-actin in a 1:1 ratio, Tβ4 controls how quickly and extensively cells build or dismantle their internal scaffolding, which in turn governs cell shape, motility, and division ^[1][2]. This ability to regulate cytoskeletal dynamics is what makes Tβ4 a potent promoter of directed cell migration — the essential first step in wound closure and tissue repair. Researchers identified a specific seven-amino-acid actin-binding motif (corresponding closely to the TB-500 fragment, Ac-LKKTETQ, residues 17–23) as the key site responsible for the peptide's angiogenic and cell-migratory effects; synthetic peptides lacking any portion of this motif lose their angiogenic activity entirely ^[3].

Beyond actin binding, Tβ4 operates as a multi-functional 'moonlighting' protein: when secreted into the extracellular space after tissue injury, it triggers a wider cascade of repair signals ^[4]. It forms a complex with integrin-linked kinase (ILK) and PINCH, activating the survival kinase Akt (protein kinase B), which promotes cell survival and blocks apoptosis ^[2]. A separate N-terminal region of the molecule contains the tetrapeptide Ac-SDKP, which independently promotes cell survival ^[19]. Additionally, Tβ4 suppresses NF-κB transcriptional activity — a master switch for inflammatory gene expression — thereby reducing the production of pro-inflammatory cytokines and dampening excessive inflammatory responses ^[15][16]. It also upregulates VEGF expression, driving the formation of new blood vessels (angiogenesis) needed to supply oxygen and nutrients to healing tissue ^[14].

Where the evidence stands

The preponderance of TB-500 and Tβ4 research is preclinical. A 2026 scoping review that searched PubMed, Europe PMC, and ClinicalTrials.gov through March 2026 identified 80 studies across tissue healing contexts; outcome categories were led by molecular/cellular markers (47.5% of studies) and healing/repair endpoints (26.3%), with the majority conducted in cell culture or animal models ^[5]. The review concluded that the mapped literature supports popular interest in several repair-related pathways but remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications — the setting of greatest public interest ^[5]. Direct evidence specifically for the TB-500 fragment (as opposed to full-length Tβ4) was limited to a single included study in that review ^[5]. Research in animal models consistently shows beneficial effects on wound closure, angiogenesis, and cardiac and corneal repair ^[6][8], and these animal findings span multiple species and model types, lending some biological plausibility to the repair mechanisms described.

Human clinical evidence exists but is narrow in scope. The most advanced clinical program involves ocular applications: RGN-259 (a Tβ4 ophthalmic solution) completed a Phase III randomized, placebo-controlled, double-masked trial in neurotrophic keratopathy patients, which showed a strong efficacy trend and a post-treatment significant difference in complete healing, though the primary endpoint was not met with statistical significance ^[11]. Phase II trials for dry eye disease have also been completed ^[12]. In cardiac settings, a small pilot trial in STEMI patients using Tβ4-pretreated endothelial progenitor cells reported improvements in left ventricular function at six months ^[10], and a separate randomized controlled trial in STEMI patients found recombinant human Tβ4 significantly reduced infarcted areas, though the authors explicitly called for further rigorous randomized studies ^[9]. Critically, TB-500 has not been approved by any regulatory agency for any human indication, is not a lawful dietary supplement ingredient, and is classified as a prohibited substance by the World Anti-Doping Agency (WADA) ^[18].

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 (Tβ4) is the full 43-amino-acid naturally occurring peptide found in nearly all human cells. TB-500 refers specifically to a shorter synthetic fragment corresponding to the central actin-binding domain of Tβ4 (residues 17–23, the heptapeptide Ac-LKKTETQ). The fragment retains core pro-angiogenic and cell-migratory properties but lacks the full structural and functional complexity of the parent peptide. Most of the published scientific literature is on full-length Tβ4, not TB-500 directly.

Is TB-500 approved by the FDA for human use?

No. TB-500 is not approved by the U.S. Food and Drug Administration for any human indication. It is not a lawful dietary supplement ingredient and has been classified as a Category 2 substance, restricting its compounding by pharmacies. RGN-259, a Tβ4-based ophthalmic formulation, has been in clinical trials for corneal conditions but has not yet received full FDA approval.

What does the research say about TB-500 for wound healing?

Preclinical studies using full-length Thymosin Beta-4 consistently show accelerated wound closure, improved re-epithelialization, increased collagen deposition, and enhanced angiogenesis in animal models. Phase II human wound healing studies showed promising results. However, a 2026 scoping review noted the overall literature remains largely preclinical, and direct evidence for the TB-500 fragment specifically — as opposed to full-length Tβ4 — is extremely limited.

Is TB-500 banned in sport?

Yes. As of the 2026 WADA Prohibited List, both TB-500 and Thymosin Beta-4 are classified as prohibited substances under the Growth Factors and Growth Factor Modulators category, banned both in and out of competition. Athletes subject to anti-doping rules governed by WADA or their sport's governing body should not use any thymosin compound.

How does TB-500 (Thymosin Beta-4) affect inflammation?

Research indicates that Tβ4 suppresses the NF-κB transcriptional signaling pathway — a central regulator of inflammatory gene expression — thereby reducing the production of pro-inflammatory cytokines such as IL-1β, IL-18, and TNF-α. It also appears to upregulate the anti-inflammatory microRNA miR-146a, which dampens Toll-like receptor (TLR) signaling. These findings come from cell culture and animal studies; the full translation to human inflammatory conditions has not been established in large-scale trials.

Has TB-500 or Thymosin Beta-4 been studied for heart repair in humans?

Yes, to a limited degree. A small pilot clinical trial reported improvements in left ventricular ejection fraction and exercise capacity in heart attack patients whose transplanted stem cells were pretreated with Tβ4. A separate randomized, placebo-controlled trial in STEMI patients found recombinant human Tβ4 significantly reduced infarcted areas. The authors of that latter study explicitly called for further rigorous randomized trials before clinical conclusions can be drawn.

Does Thymosin Beta-4 promote hair growth?

Animal studies have demonstrated that Tβ4 can activate hair follicle stem cells and accelerate hair regrowth in mice. This line of research began as an accidental observation during wound-healing experiments. However, all evidence is from animal models using forced depilation — it does not replicate conditions such as androgenetic alopecia in humans — and no regulatory authority has approved any Tβ4-based treatment for hair loss.

What is the regulatory status of TB-500 in Canada?

TB-500 does not have a Drug Identification Number (DIN) or Natural Health Product Number (NPN) from Health Canada for any approved human therapeutic use. As with all research peptides in Canada, it may only be legally handled in a legitimate laboratory research context. Researchers are advised to consult current Health Canada guidance and ensure compliance with all applicable regulations before working with this compound.

Is there evidence that TB-500 helps with tendon or ligament repair?

Animal studies suggest that Thymosin Beta-4 can support repair in connective tissues, primarily through enhanced cell migration and angiogenesis. However, a 2026 scoping review found that musculoskeletal evidence — covering tendons, ligaments, cartilage, and spine — was among the sparsest in the literature, with human clinical trials in this area entirely absent. The gap between preclinical animal findings and human evidence is particularly wide for musculoskeletal applications.

What are the known safety concerns with TB-500?

Clinical trials using Tβ4-based ophthalmic solutions (e.g., RGN-259) have reported a generally favorable local safety profile with limited adverse events. However, long-term safety data for systemic use in humans are absent, as no systemic TB-500-specific human trials have been completed. Regulatory bodies have flagged the lack of adequate human safety and efficacy data for injectable use as a key concern. Researchers should consult relevant safety literature before designing any in vitro or preclinical protocols.

Glossary

Thymosin Beta-4 (Tβ4)

A naturally occurring 43-amino-acid peptide found in virtually all nucleated cells, functioning as the body's primary G-actin sequestering molecule and playing broad roles in cell migration, wound repair, angiogenesis, and anti-inflammatory signaling.

G-actin sequestration

The process by which Tβ4 binds to free globular actin (G-actin) monomers, preventing them from polymerizing into filaments and thereby regulating cytoskeletal dynamics and cell motility.

Angiogenesis

The formation of new blood vessels from existing vasculature, an essential process in wound healing and tissue repair that Tβ4 has been shown to promote through VEGF upregulation and endothelial cell activation.

Integrin-Linked Kinase (ILK)

A signaling enzyme that Tβ4 complexes with alongside PINCH protein, resulting in activation of the pro-survival kinase Akt and suppression of apoptosis in injured cells.

NF-κB

Nuclear Factor kappa-light-chain-enhancer of activated B cells, a master transcriptional regulator of inflammation whose suppression by Tβ4 is a proposed mechanism for the peptide's anti-inflammatory effects.

Re-epithelialization

The migration and proliferation of epithelial cells (such as keratinocytes in skin or epithelial cells in the cornea) to cover a wound surface, a key early step in tissue repair that Tβ4 has been shown to accelerate.

Neurotrophic keratopathy

A degenerative corneal disease caused by impaired corneal innervation, leading to persistent epithelial defects that resist normal healing; a condition for which Tβ4-based RGN-259 has been evaluated in Phase III clinical trials.

WADA Prohibited List

The annual list of substances and methods prohibited in sport published by the World Anti-Doping Agency; TB-500 and Thymosin Beta-4 are classified as prohibited substances under the Growth Factors and Growth Factor Modulators category, banned both in and out of competition.

References

1. A Tobacco-Derived Thymosin β4 Concatemer Promotes Cell Proliferation and Wound Healing in Mice — PMC / PLoS ONE
2. TMSB4 Overexpression Enhances the Potency of Marrow Mesenchymal Stromal Cells for Myocardial Repair — PMC / Frontiers in Cardiovascular Medicine
3. The actin binding site on thymosin β4 promotes angiogenesis — FASEB Journal
4. Thymosin beta-4 — an overview (ScienceDirect Topics) — ScienceDirect / Elsevier
5. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — Preprints.org (scoping review, 2026)
6. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent — PubMed / Clinical Ophthalmology (2007)
7. Thymosin beta-4 — Wikipedia (hair growth and wound healing sections) — Wikipedia (citing peer-reviewed sources including Philp et al. 2004)
8. Cardioprotection by Thymosin Beta 4 — ScienceDirect / Progress in Molecular Biology and Translational Science
9. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion — PubMed (2025)
10. Clinical Trial: Elevated Thymosin Beta 4 Plasma Levels Are Associated with Improvement After Stem Cell Therapy in Ischemic Heart Failure (REGENERATIVE-IHD trial) — TCTMD / RegeneRx press release citing peer-reviewed publication
11. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial — PMC / Journal of Clinical Medicine (2022)
12. Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis — PubMed / Experimental Eye Research (2023)
13. Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function — PubMed / Investigative Ophthalmology & Visual Science (2026)
14. Thymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model — PMC / International Journal of Molecular Sciences (2020)
15. Thymosin β4 Mitigates Acute Cerebral Infarction Via Inhibition of the TLR4/NF-κB Pathway and Suppression of Neuronal Pyroptosis — Springer / Applied Biochemistry and Biotechnology (2026)